New journal looks at hot button issue

First Lady Michelle Obama's recent announcement of a campaign to end childhood obesity was not lost on medical publisher Mary Ann Liebert, Inc., which will roll out a new journal, Childhood Obesity, in June 2010.

The journal represents a re-branding of Liebert's Obesity and Weight Management, which will be folded into the new title. Vicki Cohn, executive VP and managing editor at Liebert, said the decision to focus the journal on childhood obesity was “not an advertising thing,” but reflects “the enormous problem” of childhood obesity.

“It's a hot subject,” said Cohn.

The re-branded, peer-reviewed Childhood Obesity will offer original articles, perspectives from opinion leaders, safety and efficacy treatment regimens and case reports, among other features, to physicians, nurses and other healthcare professionals, according to a company statement.  

Cohn said Liebert has “maintained steady advertising sales” across its journal portfolio, which includes flagship Genetic Engineering and Biotechnology News, ASSAY and Drug Development Technologies, and AIDS Research and Human Retroviruses, among others covering biotechnology, medicine, surgery, nursing and integrative medicine.

Liebert titles are primarily subscription-based, said Cohn, adding that the company's journals go out to 140 countries. For 2010, 15 Liebert titles will increase the number of issues published each year, according to the website.

“Mrs. Obama is right when she says that childhood obesity threatens the nation's economic health,” said Mary Ann Liebert, the company's namesake president and CEO, in a statement. “The costs of health care related to obesity-related conditions such as diabetes and heart disease are enormous. Healthy people are productive people. Weight management starts in childhood.”
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.